在TNBC中,与炎症相关的耐药性和瘤生长
Arij Fouzat Hassan1, Hadeel Kheraldine2, Lama Abujamous2
1College of Pharmacy, Department of Pharmaceutical Sciences, QU Health, Qatar University, Doha, Qatar.
Frontiers in immunology
|September 11, 2025
概括
三阴性乳腺癌 (TNBC) 是由瘤微环境 (TME) 内的炎症和细胞因子驱动的. 针对这些因素提供了新的治疗策略,以克服TNBC的治疗耐药性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 三重阴性乳腺癌 (TNBC) 缺乏向治疗选择,依赖于有限成功的化疗.
- 瘤微环境 (TME) 和由TNF-α,TGF-β,IL-6和IL-10等细胞因子驱动的慢性炎症是TNBC进展的关键.
- 这种炎症性TME促进瘤生长,转移,免疫抑制和治疗耐药性.
研究的目的:
- 审查细胞因子,炎症和TME在TNBC病原和耐药性的复杂相互作用.
- 评估针对TNBC炎症轴的当前和新兴治疗策略.
主要方法:
- 临床前和临床研究的文献综述.
- 关键检查链接细胞因子,炎症,TME和TNBC的机制.
- 针对细胞因子信号的治疗方法的评估.
主要成果:
- 由炎症性细胞因子推动的TME创造了一个免疫抑制的利基,驱动TNBC.
- 细胞因子失调促进瘤的扩散,转移和对传统疗法的抵抗.
- 准细胞因子信号传递是克服TNBC耐药性的有希望的途径.
结论:
- 了解细胞因子驱动的炎症性TME对于TNBC治疗至关重要.
- 针对炎症轴对TNBC具有显著的治疗潜力.
- 需要进一步的研究来了解这些新兴疗法的复杂性.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K


